CL2015003679A1 - Agentes terapéuticos para el uso en la profilaxis y/o el tratamiento de trastornos del movimiento hiperquineticoico - Google Patents
Agentes terapéuticos para el uso en la profilaxis y/o el tratamiento de trastornos del movimiento hiperquineticoicoInfo
- Publication number
- CL2015003679A1 CL2015003679A1 CL2015003679A CL2015003679A CL2015003679A1 CL 2015003679 A1 CL2015003679 A1 CL 2015003679A1 CL 2015003679 A CL2015003679 A CL 2015003679A CL 2015003679 A CL2015003679 A CL 2015003679A CL 2015003679 A1 CL2015003679 A1 CL 2015003679A1
- Authority
- CL
- Chile
- Prior art keywords
- treatment
- prophylaxis
- therapeutic agents
- movement disorders
- hyperkinetic movement
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
- A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
- A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/04—Chelating agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Toxicology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13382230 | 2013-06-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2015003679A1 true CL2015003679A1 (es) | 2016-09-02 |
Family
ID=48672545
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2015003679A CL2015003679A1 (es) | 2013-06-19 | 2015-12-18 | Agentes terapéuticos para el uso en la profilaxis y/o el tratamiento de trastornos del movimiento hiperquineticoico |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US9789072B2 (enExample) |
| EP (1) | EP3010543B1 (enExample) |
| JP (1) | JP6476174B2 (enExample) |
| KR (1) | KR102254542B1 (enExample) |
| CN (1) | CN105658238B (enExample) |
| AU (1) | AU2014283319B2 (enExample) |
| BR (1) | BR112015031835B1 (enExample) |
| CA (1) | CA2915811C (enExample) |
| CL (1) | CL2015003679A1 (enExample) |
| DK (1) | DK3010543T3 (enExample) |
| ES (1) | ES3053333T3 (enExample) |
| IL (1) | IL243192B (enExample) |
| MX (1) | MX366353B (enExample) |
| PL (1) | PL3010543T3 (enExample) |
| PT (1) | PT3010543T (enExample) |
| RU (1) | RU2685502C2 (enExample) |
| SG (1) | SG11201510451RA (enExample) |
| WO (1) | WO2014202646A1 (enExample) |
| ZA (1) | ZA201600312B (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA41557A (fr) * | 2015-02-18 | 2017-12-26 | Auspex Pharmaceuticals Inc | Inhibiteurs diméthoxyphényles du transporteur vésiculaire des monoamines 2 |
| CA3076000A1 (en) * | 2017-09-21 | 2019-03-28 | Neurocrine Biosciences, Inc. | High dosage valbenazine formulation and compositions, methods, and kits related thereto |
| US20200230127A1 (en) | 2017-10-10 | 2020-07-23 | Neurocrine Biosciences, Inc. | Methods for the Administration of Certain VMAT2 Inhibitors |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE790165A (fr) * | 1971-12-14 | 1973-02-15 | Parke Davis & Co | Nouveaux aminoalcanols et procede pour les preparer |
| ES2569483T3 (es) | 2007-06-21 | 2016-05-11 | Amgen Inc. | Métodos para sintetizar cinacalcet y sales del mismo |
| CL2008002793A1 (es) * | 2007-09-20 | 2009-09-04 | Cgi Pharmaceuticals Inc | Compuestos derivados de amidas sustituidas, inhibidores de la actividad de btk; composicion farmaceutica que los comprende; utiles en el tratamiento del cancer, trastornos oseos, enfermedades autoinmunes, entre otras |
| US8197858B2 (en) | 2009-02-06 | 2012-06-12 | Mark John Zamoyski | Bone microenvironment modulated seizure treatments |
| EP2705842A1 (en) * | 2012-09-05 | 2014-03-12 | Pharnext | Therapeutic approaches for treating parkinson's disease |
| RS53227B (sr) * | 2011-03-01 | 2014-08-29 | Pharnext | Terapija neuroloških poremećaja kombinacijom baklofena i akamprosata |
| UA115968C2 (uk) | 2011-03-01 | 2018-01-25 | Фарнекст | Нові композиції для лікування неврологічних захворювань |
-
2014
- 2014-06-18 JP JP2016520456A patent/JP6476174B2/ja active Active
- 2014-06-18 AU AU2014283319A patent/AU2014283319B2/en active Active
- 2014-06-18 DK DK14731261.5T patent/DK3010543T3/da active
- 2014-06-18 CA CA2915811A patent/CA2915811C/en active Active
- 2014-06-18 PL PL14731261.5T patent/PL3010543T3/pl unknown
- 2014-06-18 MX MX2015018040A patent/MX366353B/es active IP Right Grant
- 2014-06-18 WO PCT/EP2014/062786 patent/WO2014202646A1/en not_active Ceased
- 2014-06-18 EP EP14731261.5A patent/EP3010543B1/en active Active
- 2014-06-18 BR BR112015031835-5A patent/BR112015031835B1/pt active IP Right Grant
- 2014-06-18 PT PT147312615T patent/PT3010543T/pt unknown
- 2014-06-18 ES ES14731261T patent/ES3053333T3/es active Active
- 2014-06-18 RU RU2016101152A patent/RU2685502C2/ru active
- 2014-06-18 KR KR1020167001456A patent/KR102254542B1/ko active Active
- 2014-06-18 CN CN201480040973.6A patent/CN105658238B/zh active Active
- 2014-06-18 US US14/900,028 patent/US9789072B2/en active Active
- 2014-06-18 SG SG11201510451RA patent/SG11201510451RA/en unknown
-
2015
- 2015-12-17 IL IL243192A patent/IL243192B/en active IP Right Grant
- 2015-12-18 CL CL2015003679A patent/CL2015003679A1/es unknown
-
2016
- 2016-01-14 ZA ZA2016/00312A patent/ZA201600312B/en unknown
-
2017
- 2017-09-22 US US15/713,372 patent/US20180042869A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112016009995A2 (pt) | compostos agonistas triplos glucagon-glp-1-gip | |
| ECSP19021223A (es) | Derivado de glucagon, conjugado del mismo, composición que comprende el mismo y uso terapéutico del mismo | |
| CL2015002733A1 (es) | Composición farmacéutica de clorhidrato de s-cetamina. | |
| CL2015000942A1 (es) | Compuestos de benceno sustituido. | |
| CL2015001358A1 (es) | Potenciadores del cftr deuterados | |
| CR20150472A (es) | USO DE DERIVADOS DE PIRAZOLOPIRIMIDINA PARA EL TRATAMIENTO DE TRANSTORNOS RELACIONADOS CON LA PI3Kd | |
| MX383499B (es) | Agentes terapeuticos para enfermedades neurodegenerativas | |
| SV2015005115A (es) | Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades | |
| BR112016009889A2 (pt) | ?compostos agonistas duplos gip-glp-1 e métodos? | |
| CY1120173T1 (el) | Ενωση πυραζολο-αμιδιου και φαρμακευτικες χρησεις αυτης | |
| CL2015003690A1 (es) | Uso de pridopidina o una sal de la misma para preparar un medicamento útil en el tratamiento de la enfermedad de huntington. | |
| BR112015024411A2 (pt) | desaza-purinonas macrocíclicas para o tratamento de infeções virais | |
| MX390084B (es) | Moduladores del receptor p2x3 y p2x2/3 de diaminopirimidina para usarse en el tratamiento de la tos. | |
| MX2016001400A (es) | Derivados de piridazina 1,4-disustituida, y su uso para el tratamiento de afecciones relacionadas con la deficiencia de smn. | |
| MX374944B (es) | Derivado de piranocromenil fenol, y composición farmacéutica para tratar un síndrome metabólico o enfermedad inflamatoria. | |
| BR112017011168A2 (pt) | medicamentos para retardar a doença de parkinson | |
| CL2016000019A1 (es) | Compuestos derivados de dihidroxifenilo deuterado o una sal de los mismos; composición farmacéutica que los comprende y su uso para el tratamiento de trastornos mediados por neurotransmisores tales como hipotensión, trastornos del sueño, enfermedad de alzheimer y depresión. | |
| AR094707A1 (es) | Compuesto de quinazolin-4-amina, composición farmacéutica que lo comprende y su uso para el tratamiento de una enfermedad mediada por la quinasa rip2 | |
| AR110404A1 (es) | MÉTODOS PARA EL TRATAMIENTO DE ENFERMEDADES FIBRÓTICAS UTILIZANDO EL INTERFERÓN-l | |
| BR112018006206A2 (pt) | composição, uso de uma combinação, forma de dosagem fixa farmacêutica, combinação de dosagem fixa, embalagem, e, uso de uma combinação de dose fixa | |
| BR112017021583A2 (pt) | métodos para o tratamento de transtornos inflamatórios | |
| CL2016000884A1 (es) | Derivados de piperazina y su uso como medicamento. | |
| UY36732A (es) | Piridin pirazinonas novedosas como inhibidores de bromodominios de la familia bet | |
| MX2018002298A (es) | Metodos de uso de interleucina 10 para el tratamiento de enfermedades y trastornos. | |
| MX366353B (es) | Agentes terapeuticos para uso en la profilaxis y/o tratamiento de trastornos de movimiento hipercinetico. |